Catalent’s Schorndorf Facility Celebrates 50 Years of Excellence in Pharmaceutical Development, Manufacturing, and Packaging
Schorndorf, GERMANY, 10 March 2011— Catalent Pharma Solutions, a leading provider of drug and biologic development services, delivery technologies and supply solutions, celebrates the 50th anniversary of its Schorndorf, Germany facility which specializes in modified release technologies and clinical supply services.
“We are extremely proud of Schorndorf’s rich 50-year history and proven excellence in providing a full-range of services and innovative solutions to meet the increasingly complex needs of our customers,” stated Ian Muir, PhD, President, Modified Release Technologies, Catalent Pharma Solutions. “Our focus on reliability combined with our diverse employee base, and long-term customer partnerships, have made us successful in broadening Schorndorf’s roots and optimizing our offerings.”
The Schorndorf facility has been supporting global pharmaceutical companies such as Lilly. “Over the years Lilly has established an enduring partnership with Catalent Germany Schorndorf GmbH,” commented Sherman Whitfield, Director in Office of Alliance Management of Lilly. Mr. Whitfield will be joining the celebration and speaking to the employees to congratulate them on the excellent work that they are doing for Lilly.
The Catalent Germany Schorndorf GmbH facility first opened in 1961 as Allpack, and quickly grew, focusing on the pharmaceutical industry and extending its reach internationally and excelling in service areas such as clinical supply, manufacturing, quality control and research and development (R&D), the hallmark offerings for which the facility is presently known. In recent years, Schorndorf’s deep expertise, diverse and experienced work force, and long-term customer relationships have enabled it to double Good Manufacturing Practices (GMP) production space in 2000, build a new distribution center for clinical trial medication in 2005, and later double the laboratory in 2010.
“We are committed to providing reliable services to our customers for more products and better treatment. Catalent will continue to invest in the Schorndorf facility and has begun construction work to double the clinical supply warehouse capacity”, stated Peter Brun, Site Leader of Clinical Supply Services at the Catalent Germany Schorndorf GmbH facility.
“A good reputation and confidence in the capability of a service provider are particularly vital in the pharmaceutical industry,” said Eric Schmidhaeuser, Managing Director at the Catalent Germany Schorndorf GmbH facility. “These assets can be earned only through reliable supply, excellent quality and innovative solutions that lead to customer satisfaction. Fifty years of Catalent Germany Schorndorf GmbH are testament to this standard of excellence.”
To commemorate its 50th anniversary, the Schorndorf facility is hosting a full-day celebration on 10 March that will include facility tours, a visit to the Mercedes-Benz museum and a gala dinner. The celebration will feature remarks from Mr. John Chiminski, President and Chief Executive Officer (CEO) of Catalent Pharma Solutions, as well as presentations from Dr. Ian Muir, President of Modified Release Technologies and Mr. Scott Houlton, President of the Development and Clinical Services business. Guest speakers will be Mr. Bernd Würsching the General Manager Production Planning Cayenne / Panamera (Porsche AG).
To learn more about the Modified Release Technologies or Clinical Supply Services offered at Catalent’s Schorndorf facility and worldwide, go to:
For specific inquiries or to arrange a site tour of Catalent’s Schorndorf facility, please contact Eric Schmidhaeuser, General Manager of the Catalent Germany Schorndorf GmbH facility at Eric.Schmidhaeuser@catalent.com.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 28 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.
more products. better treatments. reliably supplied.™